PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Design and Evolution: Molecular Sleuthing Reveals Drug Selectivity
June 2015
Families in Gene Neighborhoods
June 2015
Ryanodine Receptor
April 2015
CCR5 and HIV Infection
January 2015
Drug Targets: Bile Acids in Motion
September 2014
Drug Targets: S1R's Ligands and Partners
September 2014
P2Y Receptors and Blood Clotting
September 2014
Bacterial CDI Toxins
June 2014
Glucagon Receptor
April 2014
Viroporins
March 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Design and Discovery: Virtual Drug Screening
January 2014
Cancer Networks: IFI16-mediated p53 Activation
November 2013
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Finding Druggable Targets
October 2013
Drug Discovery: Identifying Dynamic Networks by CONTACT
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Infectious Diseases: Determining the Essential Structome
May 2013
NDM-1 and Antibiotics
May 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Cytochrome Oxidase
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Regulatory insights
September 2012
Solute Channels
September 2012
Pocket changes
July 2012
Receptor bias
July 2012
Anthrax Stealth Siderophores
June 2012
G Protein-Coupled Receptors
May 2012
Substrate specificity sleuths
April 2012
Reading out regioselectivity
December 2011
Superbugs and Antibiotic Resistance
December 2011
Terminal activation
December 2011
A change to resistance
November 2011
Docking and rolling
October 2011
Breaking down the defenses
September 2011
A2A Adenosine Receptor
May 2011
Cell wall recycler
May 2011
Subtly different
March 2011
CXCR4
January 2011
Subtle shifts
January 2011
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Peptidoglycan binding: Calcium-free killing
June 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Antibiotics and Ribosome Function
March 2010
Safer Alzheimer's drugs?
March 2010
Anthrax evasion tactics
September 2009
GPCR subunits: Separate but not equal
September 2009
Antibiotic target
August 2009
Salicylic Acid Binding Protein 2
August 2009
Lysostaphin
July 2009
Tackling influenza
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Anthrax stealth molecule
March 2009
Drug targets to aim for
February 2009
High-energy storage system
February 2009
Transporter mechanism in sight
February 2009
Scavenger Decapping Enzyme DcpS
November 2008
Blocking AmtB
September 2008

Research Themes Drug discovery

Subtly different

SBKB [doi:10.1038/sbkb.2011.06]
Featured Article - March 2011
Short description: The crystal structure of the D3 dopamine receptor reveals how to selectively target D2-like receptors.

The structure of D3R suggests strategies for designing therapeutics to distinguish between D2-like dopamine receptors.

Dopamine is a crucial neurotransmitter that affects many functions in the brain, acting through the five dopamine receptor subtypes. These G protein–coupled receptors (GPCRs) are further divided into subfamilies on the basis of whether they activate or deactivate adenylyl cyclase (the D1-like or D2-like receptors, respectively). Within the subfamilies, the receptors are very similar, as demonstrated by the high degree of identity between the D2-like receptors D2R and D3R. This similarity has made it difficult to selectively target D2R or D3R, which is desirable for the treatment of schizophrenia or drug abuse.

To address this challenge, Stevens and colleagues (PSI ATCG3D) solved the X-ray crystal structure of D3R in complex with the D2R and D3R inhibitor eticlopride. The structure shows that D3R has a typical GPCR seven-transmembrane domain core with multiple extracellular (ECL) and cytoplasmic (ICL) loops. Two slightly different conformational states of the ICL2 loop were seen, suggesting that this loop may modulate the activity of the receptor. Overall, D3R is structurally very similar to the β2-adrenergic receptor (β2AR), although several shifts can be seen in the positions of the helices that form the core of the receptor. Interestingly, the ionic lock—a stabilizing salt bridge interaction in GPCRs that was thought to play a major factor in stabilizing the receptors in the inactive conformation—can be seen in the D3R structure, the first time this has been shown for a GPCR structure.

Eticlopride bound D3R in a similar location as did the ligand-binding pocket in the β2AR structure, interacting with 18 different residues. Of those residues, 17 are conserved in the D2R interaction with eticlopride, in agreement with the similar affinity of D2R and D3R for eticlopride and underscoring the difficulty in targeting the two receptors individually. Using the structure of D3R, the authors generated a homology model of D2R, which revealed some subtle, but important, differences between the two receptors. Notably, differences can be seen in the extracellular half of helix I and the extracellular electrostatic surfaces, both of which could affect ligand binding. Molecular docking of R-22, a D3R-selective agonist, showed that, in addition to using the same binding pocket as eticlopride, R-22 also utilizes a second binding pocket that involves residues not conserved between the two receptors. Molecular dynamics simulations of D2R confirmed that this second binding pocket has an altered packing relative to D3R, allowing for discrimination between ligands.

Although the differences between D2R and D3R may seem minor, biochemists will no doubt be able to exploit them. The structure of D3R will be foundational to the efforts to develop inhibitors that can distinguish between these two D2-like receptors.

Steve Mason

References

  1. E.Y.T. Chien et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist.
    Science 330, 1091-1095 (2010). doi:10.1126/science.1197410

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health